ClinicalTrials.gg
CompletedNCT01783444BOLERO-6Updated Feb 26, 2021Results posted

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

A Phase 2 interventional study of Capecitabine and Exemestane in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 83 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
40th of 227
309 · median 54
Started
2013
with 8 others
Phase 2
121 of 233
20 open now
Registered
138th of 233
by date
Lead sponsor
4 of 233
Novartis Pharmaceuticals

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 40th largest by enrollment of the 227 interventional ones that give a count, is one of 9 that started in 2013, is one of 121 in phase 2, and was the 138th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This was a three-arm, randomized, open label, multi-center phase II study investigating the combination of everolimus (10mg daily) with exemestane (25mg daily) versus everolimus (10mg daily) versus capecitabine (1250mg/m2 twice daily for 14 days, 3-week cycle) in patients with estrogen-receptor positive, HER2 negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole.

Read the detailed description

The reference therapy (control arm) used in the course of this trial was the combination arm of everolimus plus exemestane. The investigational therapies in the context of this study were everolimus monotherapy and capecitabine monotherapy. All treatments were taken orally until disease progression, intolerable toxicity or withdrawal of patient's informed consent. Patients were randomly assigned with equal allocation to one of the treatment arms:

  1. Exemestane (25mg daily) in combination with everolimus (10mg daily)
  2. Everolimus (10mg daily)
  3. Capecitabine (1250mg/m2 twice daily) orally for two weeks, followed by a one week rest period in 3-weeks cycles.

Treatment assignment was stratified by the presence of visceral disease (yes vs. no). Visceral refered to lung, liver, heart, ovary, spleen, kidney, adrenal gland, malignant pleural or pericardial effusion or malignant ascites.

Randomization and Treatment Phase:

At Visit 3 all eligible patients were randomized in 1:1:1 ratio to receive everolimus (10mg daily oral tablets) in combination with exemestane (25 mg daily oral tablets), everolimus (10mg daily oral tablets) or capecitabine monotherapy (1250mg/m2 twice daily orally for two weeks followed by a one week rest period in 3-weeks cycles). Assignment was stratified by the presence of visceral disease (yes vs. no). Visceral refered to lung, liver, heart, ovary, spleen, kidney, adrenal gland, malignant pleural or pericardial effusion or malignant ascites. After randomization, study treatment started and continued until progression, intolerable toxicity or consent withdrawal. Further treatment after progression and study treatment discontinuation was at the investigator's discretion. Dose adjustment (reduction, interruption) according to safety findings was allowed. Regular safety and efficacy reviews by Data Monitoring Committee (DMC) were performed. Tumor assessments were performed every 6 weeks until disease progression. Additional evaluation were performed to confirm response at 4 weeks after it was first observed. After at least 150 PFS events had been documented per RECIST 1.1 by local assessment in each of the two following groups: (i) everolimus + exemestane arm plus everolimus monotherapy arm, and (ii) everolimus + exemestane arm plus capecitabine monotherapy arm, the frequency of tumor assessments was changed to every 12 weeks or as clinically indicated.

Follow-up phase:

Patients were followed for safety for 30 days after study treatment discontinuation. If a patient did not discontinue study treatment due to disease progression, lost to follow-up or consent withdrawal, then tumor assessments continued to be performed every 6 weeks until disease progression, death, lost to follow-up or investigator decision in patient best interest.

Survival Data Collection:

All patients were followed for survival status at least every 3 months regardless of treatment discontinuation reason and up to two years after randomization of last patient. Survival information could be obtained via phone and information were documented in the source documents and eCRF. Additional survival follow-up might be performed more frequently if a survival update was required for reporting the results or to meet safety or regulatory needs.

03

Conditions studied

  • Breast Cancer

Keywords

  • Everolimus
  • Exemestane
  • Capecitabine
  • locally advanced
  • metastatic
  • breast cancer
  • breast cancer positive for human epidermal growth factor receptor 2
  • HER2
  • HER2 positive
  • breast cancer progression
  • estrogen-receptor positive breast cancer
  • ER
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Women with locally advanced, recurrent, or breast cancer along with confirmation of estrogen-receptor positive (ER+). defined as at least one lesion ≥ 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness ≤ 5 mm) OR • Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above.

Key Exclusion Criteria:

  • Patients who received more than one chemotherapy line. Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    Capecitabine 1250 mg/m2

    Capecitabine (1250 mg/m2 twice daily) for two weeks, followed by one week rest period in 3-weeks cycles (investigational arm).

    Drug: Capecitabine

  • Experimental
    Everolimus 10 mg

    Everolimus (10 mg daily) (investigational arm).

    Drug: Everolimus

  • Active comparator
    Everolimus 10 mg + Exemestane 25 mg

    Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).

    Drug: Exemestane · Drug: Everolimus

Interventions

  • Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)

    Also known as: Capecitabine monotherapy

  • Exemestane, tablets for oral use, 25 mg per day in (locally supplied)

    Also known as: Control arm

  • Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)

    Also known as: Everolimus monotherapy, RAD001

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone

    Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.

    Time frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 39 months

Secondary outcomes

  1. Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Capecitabine Alone

    Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.

    Time frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 39 months

  2. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died by the date of analysis cut-off, OS was censored at the date of last known date patient alive.

    Time frame: Every 3 months following end of treatment visit, assessed for approximately 54 months

  3. Overall Response Rate (ORR)

    Overall Response Rate (ORR) as the proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST 1.1 This was assessed in the full patient population. Complete response is achieved when all lesions evaluated at baseline are absent at subsequent visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Only descriptive statistics.

    Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 43 months

  4. Clinical Benefit Rate (CBR)

    Clinical Benefit Rate (CBR) is defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) or Non-CR/non-PD lasting more than 24 weeks based on local investigator's assessment according to RECIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, Stable disease (SD), neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; CBR = CR+PR+SD. Only descriptive statistics.

    Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 43 months

  5. Time to Eastern Cooperative Oncology Group (ECOG) Performance Deterioration

    The Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale used to assess physical health of subjects,ranging from 0 (most active) to 5 (least active). Definitive deterioration is defined as no improvement in the ECOG status following observation of the deterioration.

    Time frame: Baseline, every 6 weeks up to about 43 months

  6. Time to 10% Definitive Deterioration in the Global Health Status / Quality of Life

    The global health status/QoL scale score of the QLQ-C30 is identified as the primary PRO variable of interest. Physical Functioning (PF), Emotional Functioning (EF) and Social Functioning (SF) scale scores of the QLQ-C30. The time to definitive 10% deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen. Definitive 10% (5-point) deterioration is defined as a decrease in score by at least 10% (5-points) compared to baseline, with no later increase above this threshold observed during the course of the study.

    Time frame: Baseline, every 6 weeks up to about 43 months

  7. Mean Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Between Week 3 and 12

    TSQM was used to measure the Patients' self-reported satisfaction or dissatisfaction with the study treatment. The differences in mean scale scores between weeks 3 and 12 comparing treatment satisfaction in the different treatment arms: everolimus + exemestane combination therapy versus everolimus monotherapy, and everolimus + exemestane combination therapy versus capecitabine monotherapy. The TSQM version 1.4 domain scores range from 0 to 100 with higher scores representing a higher satisfaction on that domain.

    Time frame: Week 3, Week 12

07

Results

Posted Feb 26, 2021

Participant flow

This study was conducted at 84 centers in 18 countries worldwide: Belgium (1), Denmark (6), Hungary (3), Ireland (3), Spain (4), Sweden (6), United Kingdom (3), United States (19), Argentina (6), Brazil (5), Peru (4), India (4), Lebanon (5), Malaysia (2), Russia (3), Thailand (3), Turkey (3) Australia (4)

Treatment Phase
Participant flow — Treatment Phase
MilestoneEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Started104103102
Safety set104103102
Completed000
Not completed104103102
Withdrew: Adverse event92019
Withdrew: Disease progression766664
Withdrew: Death222
Withdrew: Protocol violation112
Withdrew: Withdrawal by subject689
Withdrew: Administrative problems201
Withdrew: Physician decision865
Post-Treatment Efficacy Follow-Up Phase
Participant flow — Post-Treatment Efficacy Follow-Up Phase
MilestoneEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Started969391
Completed000
Not completed969391
Withdrew: Disease progression7811
Withdrew: Death975
Withdrew: Withdrawal by subject488
Withdrew: Administrative problems010
Withdrew: New cancer therapy71615
Withdrew: Followup phase completed as per protocol695352

Outcome measures

PrimaryProgression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone

Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.

Time frame:
Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 39 months
Reported as:
Median · Months
Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone
MonthsEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mg
Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone8.41 (6.60 to 9.72)6.77 (5.52 to 7.20)
Statistical analysis
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Hazard ratio (hr): 0.74 · 90% CI 0.57 to 0.97
SecondaryProgression Free Survival (PFS) - Everolimus Plus Exemestane Versus Capecitabine Alone

Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.

Time frame:
Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 39 months
Reported as:
Median · Months
Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Capecitabine Alone
MonthsEverolimus 10 mg + Exemestane 25 mgCapecitabine 1250 mg/m2
Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Capecitabine Alone8.41 (6.60 to 9.72)9.59 (8.25 to 15.05)
Statistical analysis
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Hazard ratio (hr): 1.26 · 90% CI 0.96 to 1.66
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died by the date of analysis cut-off, OS was censored at the date of last known date patient alive.

Time frame:
Every 3 months following end of treatment visit, assessed for approximately 54 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Overall Survival (OS)23.06 (19.48 to 27.96)29.27 (24.28 to 31.77)25.56 (23.82 to 33.35)
Statistical analysis
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Hazard ratio (hr): 1.27 · 90% CI 0.95 to 1.70
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Hazard ratio (hr): 1.33 · 90% CI 0.99 to 1.79
SecondaryOverall Response Rate (ORR)

Overall Response Rate (ORR) as the proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST 1.1 This was assessed in the full patient population. Complete response is achieved when all lesions evaluated at baseline are absent at subsequent visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Only descriptive statistics.

Time frame:
From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 43 months
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Overall Response Rate (ORR)21 (13.9 to 27.8)12 (6.9 to 18.2)23 (15.9 to 30.4)
SecondaryClinical Benefit Rate (CBR)

Clinical Benefit Rate (CBR) is defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) or Non-CR/non-PD lasting more than 24 weeks based on local investigator's assessment according to RECIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, Stable disease (SD), neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; CBR = CR+PR+SD. Only descriptive statistics.

Time frame:
From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 43 months
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate (CBR)
Percentage of ParticipantsEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Clinical Benefit Rate (CBR)59 (48.2 to 65.0)43 (33.5 to 50.3)53 (43.4 to 60.5)
SecondaryTime to Eastern Cooperative Oncology Group (ECOG) Performance Deterioration

The Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale used to assess physical health of subjects,ranging from 0 (most active) to 5 (least active). Definitive deterioration is defined as no improvement in the ECOG status following observation of the deterioration.

Time frame:
Baseline, every 6 weeks up to about 43 months
Reported as:
Median · Weeks
Time to Eastern Cooperative Oncology Group (ECOG) Performance Deterioration
WeeksEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Time to Eastern Cooperative Oncology Group (ECOG) Performance Deterioration72.57 (38.71 to NA)126.57 (72.14 to NA)120.00 (72.57 to NA)
Statistical analysis
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Hazard ratio (hr): 1.09 · 90% CI 0.72 to 1.66
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Hazard ratio (hr): 1.18 · 90% CI 0.78 to 1.77
SecondaryTime to 10% Definitive Deterioration in the Global Health Status / Quality of Life

The global health status/QoL scale score of the QLQ-C30 is identified as the primary PRO variable of interest. Physical Functioning (PF), Emotional Functioning (EF) and Social Functioning (SF) scale scores of the QLQ-C30. The time to definitive 10% deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen. Definitive 10% (5-point) deterioration is defined as a decrease in score by at least 10% (5-points) compared to baseline, with no later increase above this threshold observed during the course of the study.

Time frame:
Baseline, every 6 weeks up to about 43 months
Reported as:
Median · Weeks
Time to 10% Definitive Deterioration in the Global Health Status / Quality of Life
WeeksEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Time to 10% Definitive Deterioration in the Global Health Status / Quality of Life30.86 (24.29 to 78.00)23.86 (12.57 to 24.71)61.29 (36.86 to 143.71)
Statistical analysis
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Hazard ratio (hr): 0.64 · 90% CI 0.46 to 0.88
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Hazard ratio (hr): 1.33 · 90% CI 0.93 to 1.91
SecondaryMean Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Between Week 3 and 12

TSQM was used to measure the Patients' self-reported satisfaction or dissatisfaction with the study treatment. The differences in mean scale scores between weeks 3 and 12 comparing treatment satisfaction in the different treatment arms: everolimus + exemestane combination therapy versus everolimus monotherapy, and everolimus + exemestane combination therapy versus capecitabine monotherapy. The TSQM version 1.4 domain scores range from 0 to 100 with higher scores representing a higher satisfaction on that domain.

Time frame:
Week 3, Week 12
Reported as:
Mean · Unit on a scale
Mean Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Between Week 3 and 12
Unit on a scaleEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Side-effects-4.8 ± 28.88-9.1 ± 21.88-2.6 ± 22.45
Effectiveness-2.2 ± 20.151.2 ± 26.511.2 ± 21.61
Convenience-0.6 ± 12.001.0 ± 16.410.5 ± 17.67
Global satisfaction-1.0 ± 17.321.8 ± 20.802.3 ± 16.96
Statistical analysis
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Mean difference (net): 4.3 · 90% CI -3.3 to 11.9
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Mean difference (net): -2.2 · 90% CI -9.9 to 5.5
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Mean difference (net): -3.3 · 90% CI -10.4 to 3.8
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Mean difference (net): -3.3 · 90% CI -9.7 to 3.0
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Mean difference (net): -1.6 · 90% CI -5.8 to 2.5
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Mean difference (net): -1.1 · 90% CI -5.5 to 3.3
  • Everolimus 10 mg + Exemestane 25 mg vs Everolimus 10 mg · Mean difference (net): -2.7 · 90% CI -8.3 to 2.9
  • Everolimus 10 mg + Exemestane 25 mg vs Capecitabine 1250 mg/m2 · Mean difference (net): -3.3 · 90% CI -8.4 to 1.9
Post-hocAll Collected Deaths

On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 224 weeks (treatment duration ranged from 1.3 to 220.0 weeks). Deaths post treatment survival follow up were collected after the on- treatment period, up to approximately 5 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.

Time frame:
up to 224 weeks (on-treatment), up to approximately 5 years (study duration)
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
On-treatment deaths952
Post-treatment deaths625557
All deaths716059

Adverse events

Collected over Adverse events were collected from First Patient First Treatment (FPFT) up to 30 days after study drug discontinuation, for a maximum duration of 224 weeks (treatment duration ranged from 1.3 to 220.0 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus 10 mg + Exemestane 25 mg9/104 (8.7%)37/104 (35.6%)103/104 (99%)
Everolimus 10 mg5/103 (4.9%)30/103 (29.1%)100/103 (97.1%)
Capecitabine 1250 mg/m22/102 (2%)30/102 (29.4%)99/102 (97.1%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
PneumoniaInfections and infestations8/1044/1032/102
Deep vein thrombosisVascular disorders0/1040/1034/102
Acute kidney injuryRenal and urinary disorders3/1044/1032/102
General physical health deteriorationGeneral disorders4/1040/1030/102
DiarrhoeaGastrointestinal disorders1/1042/1033/102
VomitingGastrointestinal disorders2/1041/1033/102
DehydrationMetabolism and nutrition disorders1/1041/1033/102
HypotensionVascular disorders0/1040/1033/102
AnaemiaBlood and lymphatic system disorders1/1043/1031/102
PneumonitisRespiratory, thoracic and mediastinal disorders2/1043/1030/102
Most frequent other events
Showing 10 of 72
Most frequent other events
EventEverolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders3/1043/10362/102
DiarrhoeaGastrointestinal disorders36/10434/10355/102
NauseaGastrointestinal disorders35/10421/10352/102
StomatitisGastrointestinal disorders51/10445/10324/102
FatigueGeneral disorders39/10432/10334/102
CoughRespiratory, thoracic and mediastinal disorders37/10416/10318/102
Decreased appetiteMetabolism and nutrition disorders35/10432/10327/102
AnaemiaBlood and lymphatic system disorders32/10426/10322/102
Weight decreasedInvestigations31/10425/10315/102
Oedema peripheralGeneral disorders30/10422/10316/102

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Everolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2Total
Mean60.9 ± 10.4761.3 ± 9.0859.7 ± 10.5060.6 ± 10.03
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2Total
Female104103102309
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2Total
Caucasian788591254
Black1203
Asian118827
Native American3205
Other116320
ECOG Performance Status
ECOG Performance Status(Participants)Everolimus 10 mg + Exemestane 25 mgEverolimus 10 mgCapecitabine 1250 mg/m2Total
No Restrictions544857159
Only Light Work425039131
Only Self Care53412
Missing3227
08

Study locations

83 sites
  • University of California at Los Angeles Mattel Children's Hospital
    Los Angeles, California 90095, United States
  • Sharp Memorial Hospital SharpClinicalOncologyResearch
    San Diego, California 92123, United States
  • Florida Cancer Specialists Dept of Oncology (2)
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists FL Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Lahey Clinic Dept of Lahey Clinic (2)
    Burlington, Massachusetts 01805, United States
  • New England Hematology/ Oncology Associates, P.C. SC
    Newton, Massachusetts 02462, United States
  • Glacier View Research Institute - Cancer SC
    Kalispell, Montana 59901, United States
  • Trinitas Comprehensive Cancer Center SC
    Elizabeth, New Jersey 07207, United States
  • Hackensack University Medical Center Dept of Oncology
    Hackensack, New Jersey 07601, United States
  • Rutgers-New Jersey Medical School SC
    Newark, New Jersey 07101, United States
  • Oncology Hematology Care Inc Oncology Hematology Care 2
    Cincinnati, Ohio 45242, United States
  • Oklahoma Cancer Specialists and Research Institute Oklahoma Cancer Specialists
    Tulsa, Oklahoma 74136, United States
  • Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
    Chattanooga, Tennessee 37404, United States
  • The Jones Clinic SC
    Germantown, Tennessee 38138, United States
  • University of Tennessee SC
    Knoxville, Tennessee 27920-6969, United States
  • Sarah Cannon Research Institute SC (2)
    Nashville, Tennessee 37203, United States
  • The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD
    Fort Worth, Texas 76104, United States
  • University of Virginia Health Systems SC-4
    Charlottesville, Virginia 22908-0334, United States
  • Northwest Medical Specialties Dept of Onc
    Tacoma, Washington 98405, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1025ABI, Argentina
  • Novartis Investigative Site
    Posadas, Misiones, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000KZE, Argentina
  • Novartis Investigative Site
    Rio Negro, Viedma 8500, Argentina
  • Novartis Investigative Site
    Cordoba, X5016KEH, Argentina
  • Novartis Investigative Site
    Randwick, New South Wales 2031, Australia
  • Novartis Investigative Site
    Wahroonga, New South Wales 2076, Australia
  • Novartis Investigative Site
    Malvern, Victoria 3144, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Salvador, BA 41253-190, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Novartis Investigative Site
    Natal, RN 59075 740, Brazil
  • Novartis Investigative Site
    Passo Fundo, RS 99010-260, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 01317-002, Brazil
  • Novartis Investigative Site
    Aarhus, 8000 C, Denmark
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Næstved, DK-4700, Denmark
  • Novartis Investigative Site
    Odense C, DK 5000, Denmark
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
  • Novartis Investigative Site
    Vejle, 7100, Denmark
  • Novartis Investigative Site
    Budapest, HUN 1145, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Tatabanya, 2800, Hungary
  • Novartis Investigative Site
    Hyderabad, Andhra Pradesh 500 034, India
  • Novartis Investigative Site
    Pune, Maharashtra 411013, India
  • Novartis Investigative Site
    Kolkatta, West Bengal 700 053, India
  • Novartis Investigative Site
    Mumbai, 400 012, India
  • Novartis Investigative Site
    Limerick, Co Limerick, Ireland
  • Novartis Investigative Site
    Dublin 4, D04 T6F, Ireland
  • Novartis Investigative Site
    Galway, Ireland
  • Novartis Investigative Site
    Ashrafieh, 166830, Lebanon
  • Novartis Investigative Site
    Beirut, 1107 2020, Lebanon
  • Novartis Investigative Site
    Beirut, Lebanon
  • Novartis Investigative Site
    Hazmieh, 470, Lebanon
  • Novartis Investigative Site
    Saida, 652, Lebanon
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88586, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Jesus Maria, Lima 11, Peru
  • Novartis Investigative Site
    San Borja, Lima 41, Peru
  • Novartis Investigative Site
    Surquillo, Lima 34, Peru
  • Novartis Investigative Site
    Arequipa, Peru
  • Novartis Investigative Site
    Arkhangelsk, 163045, Russian Federation
  • Novartis Investigative Site
    Moscow, 115478, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 197758, Russian Federation
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Madrid, 28033, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Eskilstuna, SE-631 88, Sweden
  • Novartis Investigative Site
    Joenkoeping, 551 85, Sweden
  • Novartis Investigative Site
    Stockholm, SE-171 76, Sweden
  • Novartis Investigative Site
    Uppsala, SE-751 85, Sweden
  • Novartis Investigative Site
    Vasteras, 721 89, Sweden
  • Novartis Investigative Site
    Vaxjo, SE-351 85, Sweden
  • Novartis Investigative Site
    Songkhla, Hat Yai 90110, Thailand
  • Novartis Investigative Site
    Muang Lopburi, Lopburi 15000, Thailand
  • Novartis Investigative Site
    Muang, 40002, Thailand
  • Novartis Investigative Site
    Adana, 01330, Turkey
  • Novartis Investigative Site
    Istanbul, 34303, Turkey
  • Novartis Investigative Site
    Izmir, 35340, Turkey
  • Novartis Investigative Site
    East Kilbride, G75 8RG, United Kingdom
  • Novartis Investigative Site
    Middlesborough, TS4 3BW, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Ozguroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncol. 2018 Oct 1;4(10):1367-1374. doi: 10.1001/jamaoncol.2018.2262. PubMed 29862411 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Jul 2018, 64 months.

Results were first posted in Feb 2021, 2 years 7 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 64 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2013
First posted
Feb 5, 2013
StartActual
Feb 26, 2013
Primary completionActual
Jul 2, 2018
CompletionActual
Jul 30, 2018
Results first posted
Feb 26, 2021
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01783444
Responsible party
Sponsor
First posted
Feb 5, 2013
Start date
Feb 26, 2013
Primary completion
Jul 2, 2018
Completion
Jul 30, 2018
Results posted
Feb 26, 2021
Last update
Feb 26, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Everolimus

Start the discussion